Key Pneumococcal Vaccine Market Players:
- Pfizer Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- GlaxoSmithKline (GSK)
- Merck & Co.
- Sanofi Pasteur
- Serum Institute of India
- Walvax Biotechnology
- AstraZeneca
- CSL Limited
- Bharat Biotech
- Panacea Biotec
- Biological E
- KM Biologics
- LG Chem
- Takeda Pharmaceuticals
- Bio Farma
The present market depicts the existence of strongholds in certain regions, with Pfizer and Merck collectively exporting pneumococcal vaccines from America and Europe. Basically, their dominance in export is via an early market rollout and an aggressiveness in the commercialization of flagship products. During the same time, given these emerging landscapes, the key manufacturers and distributors are shifting the supply chain, with Serum Institute becoming one source of Gavi's pneumococcal vaccine. In the meantime, the China-based manufacturers are causing API production to speed up, to keep their rank in the global raw material supply.
Here is a list of key players operating in the global market:
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In 2026, the industry size of pneumococcal vaccine is assessed at USD 10.6 billion.
Pneumococcal Vaccine Market size was valued at USD 10 billion in 2025 and is projected to reach USD 17.1 billion by the end of 2035, rising at a CAGR of 6.2% during the forecast period, i.e., 2026-2035.
The pneumococcal vaccine market in North America is poised to dominate the global landscape with the largest share of 40% over the forecast period.
The major players in the market are Pfizer Inc., GlaxoSmithKline (GSK), Merck & Co., Sanofi Pasteur, Serum Institute of India, Walvax Biotechnology, AstraZeneca, CSL Limited, Bharat Biotech, Panacea Biotec, Biological E, KM Biologics, LG Chem, Takeda Pharmaceuticals, Bio Farma.
